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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in both sexes in United States and Europe.
1 Most patients die within 12 months and only 4% survive for five years after diagnosis. Surgical resection is the only potentially curative option. However, the absence of early symptoms or clinical-pathological markers results in diagnosis at a late, inoperable, stage in more than 80% of cases. 1, 2 Biomarkers for the early detection of PDAC or even its differentiation from chronic pancreatitis (CP) are lacking. The only serological marker described, CA19.9, may also be elevated in non-malignant conditions, such as acute and chronic pancreatitis, as well as hepatitis and biliary obstruction, 3 and has discriminating power only when high cut-off values are used. 4 We have observed that PDAC patients have circulating CD4 + T cells recognizing alpha-enolase (ENOA), a key glycolytic enzyme up-regulated in PDAC 5 and in other tumors. [6] [7] [8] [9] [10] The presence of ENOA-specific CD4 + T cells suggests the existence of anti-ENOA-antibody-producing B cells. In addition, the over-expression of this enzyme may promote the overcoming of immune tolerance, and often results in autoantibody production. 11 Notably, ENOA has been suggested as a potential biomarker of pancreatic cancer. 12 By using a serological proteome analysis (SERPA) approach, we have identified, in serum of PDAC patients, autoantibodies directed against a number of metabolic enzymes that are often up-regulated in PDAC. 13 In this paper we have evaluated: i) the expression and phosphorylation status of ENOA in PDAC cells; ii) the autoantibody response to phosphorylated ENOA in a large cohort of PDAC patients and their ability, alone or in combination with CA19.9, to discriminate PDAC patients from controls; iii) the correlation of antiphosphorylated ENOA autoantibody response and clinical-pathological variables of advanced PDAC patients treated with gemcitabine-based first-line chemotherapy.
Experimental Section
Sera Specimens. Ser/Thr/Tyr and methionine oxidation. Mass tolerance for precursor ions was 10 ppm and mass tolerance for fragment ions was 0.5 Da. Confident phosphopeptide identifications were determined using stringent filter criteria "ranked top #1; Xcorr versus charge 1.8, 2.5 for 2+, 3+ ions; mass accuracy 3 ppm; probability of randomized identification of peptide < 0.05" for database match scoring followed by manual evaluation of the results. The estimated "false discovery rate (FDR)" is lower than 1% by searching a combined forward-reversed database.
"On-blot" phosphatase treatment. CF-PAC-1 2-DE gels were electroblotted onto nitrocellulose membranes and, after 2 h blocking with 5% nonfat dry milk in PBS, were either incubated or not for 15 h at 30°C on a rocker in PBS containing 600 U/ml of lambda protein phosphatase (λPPase, Sigma Chemical Co, St. Louis, Missouri, USA), 40 μl/ml of 20 mM MnCl 2 and 40 μl/ml of λPPase buffer. The reactivity of a pool of three ENOA1,2 + sera (diluted in PBS to reach the final concentration of 0.1 mg/ml of IgG) was subsequently assessed.
Western blot with pre-adsorbed sera. A pool of three ENOA1,2 + sera was diluted in PBS to reach the final IgG concentration of 0.1 mg/ml and incubated for 15 h at 4°C on a rocker with 20 μg/ml of recombinant α-enolase (rENOA; supplementary data). The reactivity of these preadsorbed sera was evaluated by CF-PAC-1 2-DE WB as described.
Statistical analysis. All statistics were computed using the SPSS (17.0) and MedCalc softwares.
Data ranges and 95% confidence intervals (95% CI) were reported for descriptive statistics. A 2-sided P value of <0.05 was considered to be statistically significant. Association between clinicalpathological variables and the presence of anti-ENOA1,2 autoantibodies was tested by the Pearson's χ 2 test, Mantel-Haen-Haenszel test or Fisher's exact test, as appropriate. Progression-free survival (PFS) was calculated by the Kaplan-Meier product-limit method from the first day of treatment to the date of progression or death for any cause. If a patient was not dead, survival was censored at the time of the last visit. The log-rank test was used to assess differences between subgroups. The Hazard Ratio (HR) and the confidence limits at 95% were estimated for each variable using the Cox univariate model and adopting the most suitable prognostic category as the reference group. A multivariate Cox proportional Hazard model was also developed using stepwise regression (forward selection) with predictive variables that were significant at univariate analysis.
The cut-off P-values to enter in or to be removed from the multivariate model were set at 0.10 and 0.15, respectively. Multivariate logistic regression was performed to assess the diagnostic value of CA19.9 serum levels and the absence or presence of anti-ENOA1,2 autoantibodies, alone or combined, in a cohort of 98 PDAC patients and 63 controls (HS+CP) for whom both data were available. A logistic equation including the coefficients of the regression analysis was then constructed to calculate an estimation of individual patient's probability of having PDAC:
, where X x B is the coefficient B for each single confounding factor X. We then generated receiver operating characteristic (ROC) curves and compared their area under the curves (AUC, c-statistics) to measure the diagnostic accuracy of the model.
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Results Two acidic ENOA isoforms are expressed in PDAC. In agreement with previous studies, 6-9 data obtained using mRNA microarrays, immunohistochemistry and WB indicate that ENOA is upregulated in PDAC. 5 To characterize the expression of ENOA in PDAC, we used a 2-DE WB-based approach. In normal pancreatic tissues (NP, n=6), 2-DE WB using an anti-ENOA mAb identified four ENOA isoforms (named ENOA3,4,5,6). These isoforms had a similar 47 kDa molecular weight and pI ranging from 6.6 to 8 ( Figure 1A ). In surgical PDAC specimens (n=12), as well as in PDAC cell lines (CF-PAC-1, MiaPaca-2 and BxPC3), ENOA3,4,5,6 expression was increased approximately 2-fold, as compared to NP, and two more acidic isoforms (pI 6, named ENOA1,2), barely detectable in NP, became clearly apparent (fold increase > 3, Figure 1A ). Conversely, ENOA1,2 isoforms were not detected in the Saos-2 osteosarcoma cell line ( Figure 1B ). In PDAC cell lines, MALDI-MS/MS analysis confirmed that all 2-DE WB-detected isoforms were indeed ENOA isoforms (Supplementary Table 1) .
Sera from PDAC patients contain autoantibodies to ENOA1,2 isoforms. Using CF-PAC-1 cell lysates as the source of ENOA, the presence of circulating autoantibodies to PDAC-associated ENOA1,2 isoforms was analyzed by 2-DE WB in 120 sera from PDAC patients (clinical features described in Table 1 ) and reactivity was compared to that of sera from 40 HS, 46 CP, 12 AD, and 50 non-PDAC patients (Table 2 and Figure 2 ). Sixty-two percent of PDAC patients produced autoantibodies directed against ENOA1,2 (hereafter referred to as ENOA1,2 + ); conversely, such reactivity was observed in only 4% of non-PDAC and 9% of CP patient sera (Table 2) . A similar pattern of serum reactivity was observed using MiaPaCa-2 or BxPC-3 cell lines as the source of ENOA (data not shown). Of note, sera from ENOA1,2 + patients were able to recognize ENOA1,2 not only in cell line lysates but also in lysates from PDAC biopsies (data not shown).
Sera from PDAC patients contain autoantibodies to phosphorylated ENOA1,2 isoforms. The 2-DE pattern of ENOA1,2 isoforms suggested that they are phosphorylated. Next, we investigated whether autoantibodies to ENOA1,2 are directed to phosphorylated epitopes. To this purpose nitrocellulose membranes blotted from CF-PAC-1 2-DE gels were treated with λPPase, that removes phosphate groups from proteins, and the ability of ENOA1,2 + sera to react with blotted ENOA was tested. This "on-blot" λPPase treatment abolished the reactivity of ENOA1,2 + sera (Figure 3 ), while the reactivity of anti-α-enolase mAb (which does not distinguish between phosphorylated and un-phosphorylated isoforms) was not affected (Figure 3 , lower panels). This indicates that removal of phosphate groups selectively affects the reactivity of ENOA1,2 + patient sera, suggesting that they contain autoantibodies against phosphorylated ENOA1,2 isoforms.
Conversely, pre-incubation of ENOA1,2 + sera with un-phosphorylated recombinant ENOA (rENOA) did not alter their WB reactivity with ENOA1,2 (Figure 3 ). These data indicate that in PDAC sera autoantibodies to ENOA1,2 isoforms are indeed directed to phosphorylated ENOA.
To further confirm the ENOA autoantibody reactivity observed in PDAC patients, phosphorylation of all six ENOA isoforms from CF-PAC-1 2-DE gels was analyzed by MS. Nano-LC-MS/MS analysis revealed the presence of phosphorylation on a serine residue at position 419 ( 413 IEEELGpSKAK 422 ) only in ENOA1,2 isoforms (accession number 4503571) (Figure 4 ), indicating that in PDAC ENOA is phosphorylated at serine 419. These data strongly suggest that autoantibodies that recognize ENOA1,2 are predominantly directed to serine 419-phosphorylated ENOA.
The presence of autoantibodies to ENOA1,2 improves the diagnostic performance of CA19.9 in PDAC. Autoantibodies against ENOA1,2 discriminated PDAC patients from controls (HS, non-PDAC, CP and AD) with 62% sensitivity (95% CI: 52.9-70.4%) and 97% specificity (95% CI: 93.7-99.5%). In addition, anti-ENOA1,2 autoantibodies were significantly more frequent in patients with normal CA19.9 serum levels (< 37 IU/ml), as compared to patients with pathological elevation of CA19.9 (91% vs 59%, respectively, p=0.04, data not shown). This observation prompted us to test the diagnostic performance of combined CA19.9 serum levels (≥ 37 IU/mL) and anti-ENOA1,2 autoantibodies in a training set of 61 advanced PDAC patients at stage III and IV and 63 controls (HS+CP), using ROC analysis. As shown in Figure 5 , combined CA19.9/ENOA1,2 discriminated PDAC patients from controls with 95.1% sensitivity and 94% specificity, with an overall diagnostic accuracy of 94±0.02% (p=0.0001). These results were further confirmed in a validation set of 37 resectable PDAC patients. This cohort includes stage II and III patients who underwent surgery with curative intent. In this setting, the combination of elevated CA19.9 serum levels and anti-ENOA1,2 autoantibodies resulted in an overall diagnostic accuracy of 95±0.03% (p=0.0001, Figure 5 ). Thus, in both settings, detection of anti-ENOA1,2 autoantibodies usefully complemented the diagnostic performance of serum CA19.9 levels.
The antibody response to ENOA1,2 correlates with clinical outcome in advanced PDAC
patients. No significant associations were found between baseline PDAC patients' clinicalpathological characteristics (age, gender, previous surgery, histology, disease stage, Eastern
Cooperative Oncology Group performance status-ECOG PS) and the presence or absence of autoantibodies to ENOA1,2. Interestingly, in a cohort of 77 advanced PDAC patients, at stage III and IV, who were evaluable for clinical outcome upon I-line gemcitabine-based chemotherapy, the presence of autoantibodies to ENOA1,2 and disease stage were the only independent predictors of disease control (complete or partial response and stable disease; p=0.017 and p=0.033, respectively) and longer progression-free survival (PFS) (p=0.002 for both variables, Table 3 ) at multivariate analysis. Moreover, when the analysis was restricted to patients who were able to mount a humoral immune response against any of the ENOA isoforms (n=51), ENOA1,2 + patients had a highly significant reduction in the risk of progression or death as compared to patients with autoantibodies directed only against ENOA3,4,5,6 isoforms (p=0.0001 and p=0.004 for PFS and overall survival (OS), respectively), further supporting the clinical relevance of an autoantibody response to ENOA1,2 ( Figure 6 ).
Discussion
The dismal prognosis and late presentation of PDAC in most patients emphasizes the need to improve the early detection of PDAC. To this purpose, starting from the observation that the expression of ENOA is up-regulated in PDAC (at mRNA and protein levels;
http://www.genecards.org/index.shtml) [5] [6] [7] [8] 19 compared with normal pancreatic tissues, we characterized ENOA expression in PDAC and the relative autoantibody response in PDAC patients' sera. As a result of these studies, we demonstrate that two out of six ENOA isoforms (ENOA1,2) detectable by 2-DE WB are preferentially expressed in PDAC and that such isoforms are phosphorylated on serine 419. Although it is known that ENOA is phosphorylated in Ser/Thr/Tyr residues, [20] [21] [22] [23] [24] this is the first evidence that in PDAC cells ENOA is phosphorylated in serine 419.
The fact that the same phosphorylated peptide containing serine 419 was found in both ENO1,2 isoforms suggests that additional differential post-transcriptional modifications (e.g. acetylation, methylation) are responsible for their different isoelectric point. Most importantly, here we provide evidence that ENOA1,2 isoforms induce an in vivo humoral response in a substantial proportion of PDAC patients (62%). Such reactivity is presumably directed against the phosphorylated serine 419 residue and is specifically associated to PDAC, in that it is only sporadically observed in patients with inflammatory pancreatic diseases (CP), autoimmunity, and patients with non-PDAC malignancies. This would imply that the aberrant ENOA phosphorylation observed in PDAC may induce the overcoming of immune tolerance against this enzyme and trigger the antibody response. 25 Autoantibodies to ENOA3,4,5,6 isoforms have indeed been found in the serum of patients with lung carcinoma, 26-28 acute leukemia, 29 and multiple sclerosis, 30 as well as in a small proportion of HS (this paper). Conversely, we found that autoantibody production against ENOA1,2 was almost exclusively observed in PDAC patient sera.
Of clinical relevance, ENOA1,2 autoantibodies are significantly more frequent in patients with normal CA19.9 levels, potentially complementing the performance of the most widespread serological test currently employed in the diagnostic workup of both cystic and solid pancreatic masses. CA19.9 immunoassay achieves high sensitivity and specificity only in the presence of a considerable tumor burden and when high cut-offs are used. 4 Moreover, it may be elevated in nonmalignant conditions, such as acute and chronic pancreatitis, as well as hepatitis and biliary obstruction, 3 and in other gastrointestinal and non-gastrointestinal cancers. Here we demonstrate that the combination of CA19.9 and anti-ENOA autoantibodies yields a diagnostic accuracy of approximately 95% not only in advanced PDAC patients undergoing palliative treatment, but also in patients who may be amenable to surgery with curative intent. In resectable PDAC, where the rate of abnormal CA19.9 serum level falls considerably, 31 the simultaneous detection of autoantibodies to phosphorylated ENOA1,2 could thus provide a more finely-tuned diagnostic tool and warrants further confirmation in larger surgical series as well as a potential screening method for high risk populations. 32 By 2-DE approach we provide the proof-of-concept that phosphorylated ENOA at serine 419 is specifically recognized by autoantibodies in PDAC patients. Development of a handy assay based on the capture of autoantibodies to phosphorylated serine 419 residue will allow to validate the diagnostic potential in a large cohort of patients.
Finally, ENOA1,2 + patients exhibit a more favorable clinical course with a significantly lower proportion of disease progression and a consequently longer PFS upon gemcitabine treatment.
Interestingly, this advantage seems to be restricted to patients who are able to mount a humoral immune response specifically directed against the phosphorylated isoforms ENOA1,2. This is clinically relevant in a disease, such as advanced PDAC, where only performance status and disease stage have proved to reliably predict clinical outcome. 33 The mechanism involved in the production of autoantibodies to ENOA in PDAC patients is presently unclear. In conclusion, this study indicates that serine 419-phosphorylated ENOA1,2 isoforms and the autoantibody response against them are specifically associated with PDAC and appear to influence its clinical course. Further investigations are needed to validate PDAC sera reactivity against phosphorylated ENOA1,2 in a large-scale study, as well as to fully evaluate their clinical usefulness. Representative reactivity of a pool of three ENOA1,2 + PDAC sera assessed alone on untreated membrane, alone on membrane treated "on blot" with λPPase or mixed with rENOA on untreated membrane is shown in upper panels. The reactivity of anti-α-enolase mAb is present at the bottom of each panel. Graph shows the quantisation analysis of ENOA isoforms probed by ENOA1,2 + sera.
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